Obesity and glomerular filtration rate
- PMID: 37947985
- DOI: 10.1007/s11255-023-03862-0
Obesity and glomerular filtration rate
Abstract
Obesity has received considerable attention in general medicine and nephrology over the last few years. This condition increases the risk of metabolic syndrome, diabetes mellitus, hypertension, and dyslipidemia, which are the main risk factors for developing chronic kidney disease (CKD). Kidney damage caused by obesity can be explained by many mechanisms, such as sympathetic nervous and renin-angiotensin-aldosterone systems activation, mechanical stress, hormonal unbalance, as well as inflammatory cytokines production. Even though creatinine-based glomerular filtration rate (GFR) equations in obese individuals have been validated (Salazar-Corcoran and CKD-MCQ), changes in body weight after bariatric surgery (BS) leads to changes in creatininemia, affecting its reliability. Thus, an average between creatine and cystatin-based GFR equations would be more appropriate in this setting. Bariatric surgery can reverse diabetes mellitus and improve hypertension, which are the main causes of CKD. Conclusion: GFR can be affected by obesity and BS, and its value should be cautiously evaluated in this setting.
Keywords: Bariatric surgery; Glomerular filtration rate; Obesity.
© 2023. The Author(s), under exclusive licence to Springer Nature B.V.
References
-
- KDIGO (2012) Clinical Practice Guideline for the Evaluation andManagement of Chronic Kidney Disease. Kidney Int Suppl 3(1):1–163
-
- Billeter AT, Kopf S, Zeier M, Scheurlen K, Fischer L, Schulte TM et al (2016) Renal function in Type 2 diabetes following gastric bypass. Dtsch Arzteblatt Int 113(49):827–833
-
- Provenzano M, Jongs N, Vart P, Stefánsson B, Chertow G, Langkilde AM, McMurray J, Correa-Rotter R, Rossing P, Sjöström D, Toto R, Wheeler D, Heerspink H, DAPA-CKD Trial Committees and Investigators (2022) The kidney protective effects of the sodium-glucose cotransporter-2 inhibitor dapagliflozin, are present in patients with CKD treated with mineralocorticoid receptor antagonists. Kidney Int Rep 7(3):436–443. https://doi.org/10.1016/j.ekir.2021.12.013 - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
